BIOVAXYS Aktie

 

VANCOUVER, BC, March 31, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB0) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) is providing this bi-weekly update on the status of the management cease trade order granted on March 3, 2026 (the “MCTO”), by its principal regulator, the British Columbia Securities Commission (the “BCSC”) under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”). The Company announced on March 3, 2026 (the “Default Announcement”), that it was unable to file its audited annual financial statements for the year ended October 31, 2025, the related management's discussion and analysis, and its Form 52-109FV1 CEO and CFO certifications of annual filings (collectively the “Annual Filings”). Under National Instrument 51-102 - Continuous Disclosure Obligations, the Annual Filings were required to be made not later than February 28, 2026.   The Company is actively working with its auditor, Dale Matheson Carr-Hilton LaBonte...

VANCOUVER, BC, March 17, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) is providing this bi-weekly update on the status of the management cease trade order granted on March 3, 2026 (the “MCTO”), by its principal regulator, the British Columbia Securities Commission (the “BCSC”) under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”). The Company announced on March 3, 2026 (the “Default Announcement”), that it was unable to file its audited annual financial statements for the year ended October 31, 2025, the related management's discussion and analysis, and its Form 52-109FV1 CEO and CFO certifications of annual filings (collectively the “Annual Filings”). Under National Instrument 51-102 - Continuous Disclosure Obligations, the Annual Filings were required to be made not later than February 28, 2026.   The Company is actively working with its auditor, Dale Matheson Carr-Hilton LaBonte ...

  VANCOUVER, BC and LANDERA RANCH, CA March 10, 2026 -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Adiverna LLC ("Adiverna") announce today that they have entered into a Research Agreement ("Agreement") to develop mRNA-based Rabies, Leptospirosis, Feline Infectious Peritonitis (FIV and other mRNA-based vaccines for companion animal veterinary applications (dogs and cats).  The collaboration utilizes BioVaxys' DPX™ Immune Educating Platform ("DPX") formulations with novel proprietary mRNA sequences coding for protective antigens designed and developed by Adiverna. Adiverna is pioneering a unique approach in veterinary healthcare by leveraging its proprietary artificial intelligence technology to design and optimize mRNA sequences for vaccines specifically tailored for companion animals. Currently, no mRNA vaccines are approved for these animals, making Adiverna's focus on this area groundbreaking. By utilizing mac...

Vancouver, BC – TheNewswire - March 3rd, 2026 – BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) announces that it was unable to file its annual financial statements, management's discussion and analysis and the required certifications for the year ended October 31, 2025 (the “Annual Filings”) on or before the prescribed filing deadline of February 28, 2026 (the “Annual Filing Deadline”). The Company and the auditor have been diligently working to complete the Annual Filings, however, the Company was not able to make the required filings by the Annual Filing Deadline. The primary contributing factor to the delay was a late start to the audit as a result of the Company making changes to its accounting systems and processes. The Company believes that the audit will be completed by April 28, 2026, with the annual filings to be completed as soon as possible thereafter. As a result, the Company filed an application to the British Columbia Securi...

  Reinforces Synergistic Potential and Expands Opportunity Beyond Ovarian Cancer   VANCOUVER, BC – TheNewswire - January 29, 2026 / TheNewswire / - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB:BVAXF) (“BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™ antigen delivery and immune-educating technology platform, today announced positive findings from a Phase 2 clinical study evaluating maveropepimut-S (MVP-S) in combination with pembrolizumab and low-dose cyclophosphamide in patients with advanced or metastatic bladder cancer.  These results build on the Company's recent Phase 1B/2 data in advanced ovarian cancer and further validate the potential of MVP-S to enhance checkpoint inhibitor activity across multiple solid tumor indications. The Phase 2 study, led by Oliver Rix, MD, PhD, Founder, Director, and Principal Investigator a...

Study subject Remains in Complete Response for 3 YearsExceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent ChemotherapyVancouver, British Columbia--(......

  VANCOUVER, BC, January 15th,2026/ - TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to provide an update on 1Q2026 initiatives, including collaborations and non-dilutive funding programs. The Company is pleased to announce that it is participating in a Request for Information (RFI) solicitation issued by the US Government's Biomedical Advanced Research and Development Authority (BARDA) for transformative 'New Vaccine Platforms' that can enable efficient development timelines in response to emerging infectious disease threats.  BARDAs mission is to accelerate medical countermeasure product and technology development to address evolving needs including pandemic influenza, emerging infectious diseases, and other biological threats.  The RFI issued by BARDA is the precursor to a subsequent Request for Proposal (RFP), which is issued following BARDA's assessment of novel vaccine platforms submitted during th...

Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology com......

VANCOUVER, BC, December 31st. 2025 / - TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to provide a summary of operating initiatives over the past year following the integration of the DPX™ platform into the BioVaxys business.   The Company's focus continues to drive organic growth by: Expanding its early-stage pipeline by pursuing multiple out licensing opportunities and research collaborations where the Company's DPX platform can address specific needs   Reducing internal risk & the considerable funding requirements of late-stage clinical studies by out-licensing maveropepimut-S (MVP-S) in selected indications seeking a co-development partner for DPX-formulations in infectious diseases.  Re-engagement of clinical trial investigators for continuations of phase 1 studies of DPX formulations   The Company's DPX platform is a major innovation in vaccine development that offers a solution t...

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology co......

   VANCOUVER, BC, December 15, 2025/ – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") is pleased to announce that Marianne Stanford, PhD, has joined BioVaxys as Scientific Advisor.   Dr Stanford was Vice President of R&D at the former IMV Inc, where she and her team were responsible for the development of the DPX™ vaccine portfolio. This included the study of the unique mechanism of action of the DPX platform and its safety, efficacy, and dosing schedules in preclinical models. Under her leadership, Dr. Stanford's team also demonstrated that combining DPX, cyclophosphamide and then PD-1 blockade (using antibodies such as pembrolizumab, Merck's Keytruda™) enhanced immunogenicity and thus efficacy in cancer models.  Dr. Stanford and collaborators have published numerous studies and she is named inventor on multiple patents related to the DPX platform and DPX formulations. This includes patents that explore DPX compos...

  VANCOUVER, BC, November 25, 2025 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or the “Company”) announces that, further to its news release dated November 14, 2025, it has issued 1,792,387 common shares in the capital of the Company (each a “Settlement Share”), at a deemed value of $0.23 per Settlement Share, in full and final settlement of accrued and outstanding indebtedness in the aggregate amount of $412,249 (the “Debt Settlement Transaction”).   All securities issued in connection with the Debt Settlement are subject to a statutory hold period of four months from the date of issuance in accordance with applicable securities legislation   This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state se...

   VANCOUVER, BC, November 19, 2025 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or the “Company”) announces that it has closed its previously announced non-brokered private placement financing (the “Offering”) of 11,311,676 units of the Company (the “Units”) at an issue price of $0.17 per Unit for aggregate gross proceeds of $1,922,984.92.   Each Unit consists of one common share of the Company (“Share”) and one common share purchase warrant (“Warrant”), whereby each Warrant will entitle the holder thereof to acquire one additional Share at an exercise price of $0.40 for a period of 24 months from the date of issuance.   The gross proceeds from the Offering are intended to be used to drive more organic pipeline growth by (1) pursuing multiple licensing opportunities and research collaborations with DPX where the Company's platform solutions can address specific needs or gaps, making the Company an attractive 'go-to' partner for targeted im...

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Oct. 30, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces an increase to its non-brokered private placement......

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Oct. 28, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces the conversion of outstanding......

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC, Oct. 22, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces the conversion of outstanding unsecured......

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Oct. 20, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces the conversion of outstanding......

VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") is pleased to announce that James Tartaglia, PhD, a former top R&D and commercial development executive with Sanofi Vaccines, has been appointed to the......

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it is undertaking a non-brokered private......

The APA Formalized the February 2024 BioVaxys Acquisition of the Former IMV Inc. Assets VANCOUVER, BC, Sept. 29, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce today that the Company and Horizon Technology Finance......